Utility Menu French

National Association of Pharmacy Regulatory Authorities

Provinces French

Main navigation French


Recherchez dans la base de données des Annexes nationales de médicaments

Commencez votre recherche en utilisant le nom générique du produit :

Recherche par annexe
Réinitialiser

ATTENTION : Tous les résultats de la recherche seront tirés du « National Drug Schedules » du site Web en anglais.

Nom du médicament (en anglais) Commentaire Annexe Date
Amlexanox or its salts or derivativesPDL I DEC / 13
Amlodipine or its saltsPDL I DEC / 13
Ammonium bromidePDL I DEC / 13
AmobarbitalC2 I JUN / 02
AmoxapinePDL I DEC / 13
AmphetamineC1 I JUN / 02
Amphotericin B or its salts or derivativesPDL I DEC / 13
Amprenavir or its salts or derivatives

including but not limited to fosamprenavir

I DEC / 13
Amprolium or its saltsPDL

for human use

I DEC / 13
Amrinone or its saltsPDL I DEC / 13
Amsacrine or its saltsPDL I DEC / 13
Amylocaine and its salts in preparations for topical use on mucous membranes except lozenges III SEP / 98
Amylocaine and its salts for ophthalmic or parenteral use II SEP / 98
Anagrelide or its saltsPDL I DEC / 13
Anakinra or its salts or derivativesPDL I DEC / 13
AnastrozolePDL I DEC / 13
AncestimPDL I DEC / 13
AndroisoxazoleC3 I JUN / 02
AndrostanoloneC3 I JUN / 02
AndrostenediolC3 I JUN / 02
Anetholtrithione III SEP / 98
AnidulafunginPDL I DEC / 13
AnileridineN I JUN / 02
Anisotropine and its salts II SEP / 98
Antazoline and its salts III SEP / 98
Anthralin II SEP / 98
Anti-thymocyte globulinPDL I DEC / 13
Antihemophilic factor, human II SEP / 98
AntipyrinePDL

for human use, except preparations for topical use

I DEC / 13
Antipyrine.

except otic preparations

II SEP / 98
Antipyrine..

for otic use

III SEP / 98
Apalutamide or its saltsPDL I JUL / 18
Apixaban or its derivativesPDL I DEC / 13
Apomorphine or its saltsPDL I FEB / 17
Apraclonidine or its saltsPDL I DEC / 13
Apramycin or its saltsPDL I DEC / 18
ApremilastPDL I DEC / 14
Aprepitant or its derivativesPDL

including but not limited to fosaprepitant

I DEC / 13
AprobarbitalC2 I JUN / 02
AprotininPDL I DEC / 13
Argatroban or its salts or derivativesPDL I DEC / 13
Arginine and its salts II SEP / 98
Aripiprazole or its saltsPDL I DEC / 13
Arsenic trioxidePDL I DEC / 13
Artemisia, its preparations, extracts and compounds except in trace amounts in homeopathic preparations II SEP / 98
Asenapine or its salts or derivativesPDL

including but not limited to asenapine maleate

I DEC / 13
Asfotase alfaPDL I OCT / 15
AsparaginasePDL

when sold for administration by injection

I DEC / 13
Astemizole or its saltsPDL I DEC / 13
AsunaprevirPDL I AUG / 16
Atazanavir or its saltsPDL I DEC / 13
Atenolol or its saltsPDL I DEC / 13
AtezolizumabPDL I MAY / 17
Atipamezole or its satlsPDL I DEC / 13
Atomoxetine or its saltsPDL I DEC / 13
Atorvastatin or its saltsPDL I DEC / 13
AtovaquonePDL I DEC / 13
Atracurium besilatePDL I DEC / 13
Atropine or its saltsPDL

including but not limited to atropine sulphate, in ophthalmic or parenteral preparations

I DEC / 13
AvelumabPDL I MAR / 18
Avermectin or its derivativesPDL

including but not limited to ivermectin, selamectin, doramectin for human use

I DEC / 13
Avermectin or its derivatives.PDL

For veterinary use - including but not limited to Ivermectin, selamectin, doramectin.  Ivermectin when when recommended for intramuscular injection for horses or for oral administration to dogs and cats, except doramectin. 

 

 

I DEC / 13
Avilamycin or its salts or derivativesPDL I MAR / 14
Axicabtagene ciloleucelPDL I MAR / 19
Axitinib or its salts or derivativesPDL I DEC / 13
Azacitidine or its salts or derivativesPDL I DEC / 13
Azacyclonol or its saltsPDL I DEC / 13
AzaribinePDL I DEC / 13
Azathioprine or its saltsPDL I DEC / 13
Azatidine or its saltsPDL

including but not limited to azatadine

I DEC / 13
Azelaic acidPDL I DEC / 13
Azelastine or its saltsPDL I DEC / 14
Azilsartan medoxomil or its salts or derivativesPDL I DEC / 13
Aztreonam or its saltsPDL I DEC / 13
Bacillus Calmette-Guerin vaccine I FEB / 02
Bacillus Calmette-Guérin (BCG)PDL

Including but not limited to Bacillus Calmette-Guérin (BCG), Strain TICE, when sold or recommended as an antineoplastic agent.

I NOV / 19
Bacitracin or its salts or derivativesPDL

For veterinary use

I DEC / 18
Bacitracin or its salts or derivatives .

For human use: for parenteral use

I SEP / 98
Bacitracin or its salts or derivatives ..

For human use: for topical use

U SEP / 98
Bacitracin or its salts or derivatives …

For human use: for ophthalmic use

III JUN / 06
Baclofen or its saltsPDL I DEC / 13
Bambuterol or its saltsPDL I DEC / 13
BarbitalC2 I JUN / 02
Barbituric AcidC2 I JUN / 02
Baricitinib or its saltsPDL I OCT / 18
BasiliximabPDL I DEC / 13
Bazedoxifene or its saltsPDL I DEC / 14
BecaplerminPDL I DEC / 13
BelimumabPDL I DEC / 13
Belladonna alkaloids, and their salts and derivatives except in preparations for topical use or in trace amounts in homeopathic preparations II SEP / 98
BemegridePDL I DEC / 13
Benactyzine or its saltsPDL I DEC / 13
Benazepril or its salts or derivativesPDL

including but not limited to benazepril hydrochloride

I DEC / 13
Bendamustine or its salts or derivativesPDL

including but not limited to bendamustine hydrochloride

I DEC / 13
Bendazac or its saltsPDL I DEC / 13
Benoxaprofen or its saltsPDL I DEC / 13
Benoxinate hydrochloride oxybuprocaine for ophthalmic or parenteral use II SEP / 98
BenralizumabPDL I MAY / 18
Benserazide or its saltsPDL I DEC / 13
Bentiromide II SEP / 98

1990 résultats


Footnotes

  • C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations
  • C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
  • C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
  • C4: drug is in the Controlled Drugs and Substances Act
  • C5: drug is in the Regulations Under CDSA
  • CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
  • CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
  • CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
  • CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
  • F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
  • F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
  • FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
  • N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
  • NR: drug has not been reviewed by NDSAC
  • PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
  • R: drug is in Part J of the Food and Drugs Act and listed in the Controlled Drugs and Substances Act
  • TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
  • U: drug has been reviewed by NDSAC and is unscheduled